EUVIMEDEUVIMED entdecken
Vergleichsstudie

Clinical effectiveness of baricitinib and abatacept in patients with rheumatoid arthritis

Shuji Asai iD, Nobunori Takahashi iD, Kenya Terabe, Yutaka Yoshioka, Toshihisa Kojima, Tomonori Kobayakawa, Yasumori Sobue iD, Tatsuo Watanabe, Yuji Hirano, Yasuhide Kanayama iD, Takefumi Kato, Masahiro Hanabayashi und 2 weitere

International Journal of Rheumatic Diseases · 2024

DOI: 10.1111/1756-185x.15414 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Journal of Rheumatic Diseases, 2024. Verfasst von Shuji Asai und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Azetidines, Sulfonamides, Purines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

The objective of this study was to compare the clinical effectiveness of baricitinib and abatacept in patients with rheumatoid arthritis (RA).

Methods

This study included 274 patients treated with abatacept and 241 treated with baricitinib who were followed for >52 weeks. Potential treatment selection bias was addressed by using inverse probability of treatment weighting. The paired t ‐test was used to assess differences in Clinical Disease Activity Index (CDAI) score relative to baseline. A generalized estimating equation was used to compare the two treatment groups.

Results

The estimated mean CDAI score was 18.2 at baseline and significantly decreased to 12.6 at 4 weeks, 8.9 at 12 weeks, 7.4 at 24 weeks, and 6.1 at 52 weeks in the abatacept group. The estimated mean CDAI score was 18.6 at baseline and significantly decreased to 9.5 at 4 weeks, 6.5 at 12 weeks, 5.7 at 24 weeks, and 5.5 at 52 weeks in the baricitinib group. The baricitinib group had significantly lower CDAI scores at 4, 12, and 24 weeks compared to the abatacept group. Subgroup analyses revealed that this difference was evident among patients with high disease activity and without concomitant use of methotrexate but was less pronounced among those with remission to moderate disease activity status with methotrexate use.

Conclusion

Both baricitinib and abatacept were effective in reducing disease activity in patients with RA. Baricitinib demonstrated potential advantages over abatacept in terms of early disease control, particularly in patients with high disease activity and without methotrexate use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidAzetidinesSulfonamidesPurinesPyrazolesAntirheumatic AgentsAbataceptHumansMaleMiddle AgedFemaleTreatment OutcomeTime FactorsAgedAdultRetrospective StudiesRemission InductionSeverity of Illness Index

Stichwörter der Autor:innen

Janus kinase inhibitorabataceptbaricitinibdrug effectmethotrexaterheumatoid arthritis

Substanzen

baricitinibAzetidinesSulfonamidesPurinesPyrazolesAntirheumatic AgentsAbatacept

Autor:innen und Institutionen

  • Department of Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
  • Department of Orthopedic Surgery, Aichi Medical University, Nagakute, Aichi, Japan.
  • Department of Rheumatology, Handa City Hospital, Handa, Aichi, Japan.
  • Department of Orthopedic Surgery and Rheumatology, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan.
  • Kobayakawa Orthopedic and Rheumatologic Clinic, Shizuoka, Japan.
  • Department of Rheumatology, Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Aichi, Japan.

ORCID-Profile: Shuji Asai, Nobunori Takahashi, Yasumori Sobue, Yasuhide Kanayama, Mochihito Suzuki

Zitieren

APA

Asai, S., Takahashi, N., Terabe, K., Yoshioka, Y., Kojima, T., Kobayakawa, T., Sobue, Y., Watanabe, T., Hirano, Y., Kanayama, Y., Kato, T., Hanabayashi, M., Suzuki, M., & Imagama, S. (2024). Clinical effectiveness of baricitinib and abatacept in patients with rheumatoid arthritis. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.15414

Vancouver

Asai S, Takahashi N, Terabe K, Yoshioka Y, Kojima T, Kobayakawa T, et al. Clinical effectiveness of baricitinib and abatacept in patients with rheumatoid arthritis. International Journal of Rheumatic Diseases. 2024. doi:10.1111/1756-185x.15414

BibTeX
@article{Asai2024,
  author = {Asai, Shuji and Takahashi, Nobunori and Terabe, Kenya and Yoshioka, Yutaka and Kojima, Toshihisa and Kobayakawa, Tomonori and Sobue, Yasumori and Watanabe, Tatsuo and Hirano, Yuji and Kanayama, Yasuhide and Kato, Takefumi and Hanabayashi, Masahiro and Suzuki, Mochihito and Imagama, Shiro},
  title = {Clinical effectiveness of baricitinib and abatacept in patients with rheumatoid arthritis},
  journal = {International Journal of Rheumatic Diseases},
  year = {2024},
  doi = {10.1111/1756-185x.15414}
}
Kostenlos starten →